Partnering
Mucosis has developed a novel vaccine technology, the Mimopath™ technology. This technology enables us to development of novel and more efficacious vaccines with improved patient convenience.
Based on the Mimopath™ technology, Mucosis is developing intranasal vaccines to prevent influenza and pneumococcal disease. Mucosis is interested in partnering with companies for its vaccine discovery and development pipeline.
Mucosis is also licensing the Mimopath™ vaccine technology to vaccine companies. This will boost the use of our vaccine technology in multiple vaccine programs throughout the industry, and will generate licensing revenues.
Partners.
Xendo (Leiden/Groningen, The Netherlands): The company collaborates with Xendo to further industrialize the manufacturing system of GEM materials, and to GMP-manufacture the GEM materials that will be used in Mucosis’ clinical trials.
The Laboratory for Pediatric Infectious Diseases, Radboud University Nijmegen Medical Centre (The Netherlands): The company collaborates with the Laboratory for Pediatric Infectious Diseases to develop a vaccine to prevent and treat diseases caused by pneumococcal bacteria.
Center for Vaccine Development, University Maryland Baltimore (USA): The company collaborates with the Center for Vaccine Development at the University of Maryland in Baltimore on a program targeted at the use of Mucosis’ proprietary vaccine technology for pediatric applications.
TNO (Leiden/Zeist, The Netherlands): The company collaborates with TNO to further Mucosis’s proprietary intranasal influenza vaccine. Together with TNO, the company runs a program aimed at optimization of the formulation of intranasal influenza vaccines and testing of these formulations in various animal models, including challenge models.